Mycobacterium avium complex infection in HIV/AIDS patients (Q37202852)

18 August 2017

1 reference

title

Mycobacterium avium complex infection in HIV/AIDS patients (English)

1 reference

Mycobacterium avium avium

18 August 2017

0 references

0 references

1 reference

Marcelo Corti

1

1 reference

PubMed ID

18588499

18 August 2017

Domingo Palmero

series ordinal

2

1 reference

18 August 2017

1 June 2008

1 reference

Expert Review of Anti-infective Therapy

18 August 2017

1 reference

18 August 2017

6

1 reference

18 August 2017

351-363

1 reference

18 August 2017

3

1 reference

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Mycobacterium xenopi, Mycobacterium fortuitum, Mycobacterium kansasii, and other nontuberculous mycobacteria in an area of endemicity for AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Characterization of biofilm formation by clinical isolates of Mycobacterium avium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Health impacts of environmental mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Survival of Mycobacterium avium in a model distribution system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Biosynthesis of mycobacterial lipoarabinomannan: role of a branching mannosyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Impact of Genotypic Studies on Mycobacterial Taxonomy: the New Mycobacteria of the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Sequencing of hsp65 distinguishes among subsets of the Mycobacterium avium complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Mycobacterium avium invades the intestinal mucosa primarily by interacting with enterocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Mycobacterium avium complex in the respiratory or gastrointestinal tract and the risk of M. avium complex bacteremia in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Interferon-gamma and interleukin-12 pathway defects and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

The complexity of HLA class II (DRB1, DQB1, DM) associations with disseminated Mycobacterium avium complex infection among HIV-1-seropositive whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Mycobacterium avium-induced SOCS contributes to resistance to IFN-gamma-mediated mycobactericidal activity in human macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Mycobacterium avium reduces expression of costimulatory/adhesion molecules by human monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

CD4+ T cells but Not CD8+ or gammadelta+ lymphocytes are required for host protection against Mycobacterium avium infection and dissemination through the intestinal route

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Viable Mycobacterium avium is required for the majority of human immunodeficiency virus-induced upregulation in monocytoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Adjunctive immunotherapy of mycobacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

The use of adjuvant granulocyte-macrophage colony-stimulating factor in HIV-related disseminated atypical mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

The pathophysiology of disseminated Mycobacterium avium complex disease in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Early manifestations of disseminated Mycobacterium avium complex disease: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Mycobacterium avium complex infection and AIDS: advances in theory and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Mycobacterial infection in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Comparison of methods for isolating Mycobacterium avium-intracellulare from blood of patients with AIDS

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Immune restoration disease after antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Comparative evaluation of the new version of the INNO-LiPA Mycobacteria and genotype Mycobacterium assays for identification of Mycobacterium species from MB/BacT liquid cultures artificially inoculated with Mycobacterial strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Direct identification of slowly growing Mycobacterium species by analysis of the intergenic 16S-23S rDNA spacer region (ISR) using a GelCompar II database containing sequence based optimization for restriction fragment site polymorphisms (RFLPs) for

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribosomal DNA sequencing and its integration into a routine clinical mycobacteriology laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

The yield of bone marrow biopsy and culture compared with blood culture in the evaluation of HIV-infected patients for mycobacterial and fungal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Evaluation of bone marrow and blood cultures for the recovery of mycobacteria in the diagnosis of disseminated mycobacterial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency sy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Effects of macrolides and ketolides on mycobacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Interferon-gamma therapy activates human monocytes for enhanced phagocytosis of Mycobacterium avium complex in HIV-infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Mycobacterial Lymphadenitis after Initiation of Highly Active Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

A prospective controlled multicentre study of clarithromycin in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

Factors Associated with the Development of Opportunistic Infections in HIV‐1–Infected Adults with High CD4+Cell Counts: A EuroSIDA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.351

21 January 2018

Identifiers

DOI

10.1586/14787210.6.3.351

1 reference

18 August 2017

1 reference

PubMed ID

18588499